These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

778 related articles for article (PubMed ID: 29904917)

  • 1. Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling.
    Liu C; Cao Z; Zhang W; Tickner J; Qiu H; Wang C; Chen K; Wang Z; Tan R; Dong S; Xu J
    J Cell Physiol; 2018 Nov; 233(11):8971-8983. PubMed ID: 29904917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulating calcium-mediated NFATc1 and mitogen-activated protein kinase deactivation underlies the inhibitory effects of kavain on osteoclastogenesis and bone resorption.
    Guo Q; Cao Z; Wu B; Chen F; Tickner J; Wang Z; Qiu H; Wang C; Chen K; Tan R; Gao Q; Xu J
    J Cell Physiol; 2018 Jan; 234(1):789-801. PubMed ID: 30078210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daidzin inhibits RANKL-induced osteoclastogenesis in vitro and prevents LPS-induced bone loss in vivo.
    Wei G; Liang T; Wei C; Nong X; Lu Q; Zhao J
    J Cell Biochem; 2019 Apr; 120(4):5304-5314. PubMed ID: 30378146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
    Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G
    Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
    Li L; Sapkota M; Gao M; Choi H; Soh Y
    Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neferine suppresses osteoclast differentiation through suppressing NF-κB signal pathway but not MAPKs and promote osteogenesis.
    Chen S; Chu B; Chen Y; Cheng X; Guo D; Chen L; Wang J; Li Z; Hong Z; Hong D
    J Cell Physiol; 2019 Dec; 234(12):22960-22971. PubMed ID: 31127627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neohesperidin suppresses osteoclast differentiation, bone resorption and ovariectomised-induced osteoporosis in mice.
    Tan Z; Cheng J; Liu Q; Zhou L; Kenny J; Wang T; Lin X; Yuan J; Quinn JMW; Tickner J; Hong G; Qin A; Zhao J; Xu J
    Mol Cell Endocrinol; 2017 Jan; 439():369-378. PubMed ID: 27664516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cajaninstilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways.
    Sun Y; Liu Y; He W; Wang C; Tickner J; Kuek V; Zhou C; Wang H; Zou X; Hong Z; Yang F; Shao M; Chen L; Xu J
    J Cell Physiol; 2019 Jul; 234(7):11792-11804. PubMed ID: 30515822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)-Epigallocatechin-3-gallate inhibits RANKL-induced osteoclastogenesis via downregulation of NFATc1 and suppression of HO-1-HMGB1-RAGE pathway.
    Nishioku T; Kubo T; Kamada T; Okamoto K; Tsukuba T; Uto T; Shoyama Y
    Biomed Res; 2020; 41(6):269-277. PubMed ID: 33268671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis.
    Ye X; Jiang J; Yang J; Yan W; Jiang L; Chen Y
    Acta Biochim Biophys Sin (Shanghai); 2022 Aug; 54(8):1080-1089. PubMed ID: 35929595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palmitoleic Acid Inhibits RANKL-Induced Osteoclastogenesis and Bone Resorption by Suppressing NF-κB and MAPK Signalling Pathways.
    van Heerden B; Kasonga A; Kruger MC; Coetzee M
    Nutrients; 2017 Apr; 9(5):. PubMed ID: 28452958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
    Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
    Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
    Chen G; Xu Q; Dai M; Liu X
    Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
    Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
    Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.
    Hong G; Chen Z; Han X; Zhou L; Pang F; Wu R; Shen Y; He X; Hong Z; Li Z; He W; Wei Q
    Clin Transl Med; 2021 May; 11(5):e392. PubMed ID: 34047464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.